Stocks · News reference
HeartFlow presented new clinical data at the Transcatheter Cardiovascular Therapeutics (TCT) symposium demonstrating that CT-guided PCI planning matches gold-standard imaging outcomes with improved procedural efficiency.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
HeartFlow announced that prospective clinical outcomes from the DECIDE registry, showing a 34% reduction in major cardiovascular events, will be presented at the AHA Scientific Sessions 2026.
Heartflow announced landmark clinical data from the P4 randomized trial showing CT-guided PCI planning matches gold-standard IVUS outcomes for one-year clinical results while reducing procedure time by 27% and contrast volume by 12%. The NAVIGATE-PCI registry demonstrated that Heartflow PCI Navigator modified treatment plans in approximately 70% of patients, primarily affecting stent length and lesion preparation decisions.
Elucid Bioimaging Inc. has acknowledged a lawsuit filed by HeartFlow, Inc. on October 22, 2026, and stated its intent to defend against the claims.
A recent SEC filing indicates that an insider at HeartFlow, Inc. sold shares of the company's stock valued at approximately $1.32 million.